Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Phase 2

Completed

Conditions: Staphylococcal Infection

Interventions: Drug: Trimethoprim-sulfamethoxazole
Other: Placebo
Drug: Clindamycin

First Posted Date: 2008-08-08

Last Posted Date: 2016-03-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1310

Registration Number: NCT00730028

Locations: 🇺🇸
Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States
🇺🇸
The University of Chicago - Comer Children's Hospital - Infectious Diseases, Chicago, Illinois, United States
🇺🇸
San Francisco General Hospital - Infectious Diseases, San Francisco, California, United States

and more 3 locations

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Phase 2

Completed

Conditions: Staphylococcal Infection

Interventions: Other: Placebo
Drug: Clindamycin
Drug: Cephalexin
Drug: Trimethoprim-sulfamethoxazole

First Posted Date: 2008-08-08

Last Posted Date: 2015-02-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2265

Registration Number: NCT00729937

Locations: 🇺🇸
University of California Los Angeles - Olive View Medical Center, Sylmar, California, United States
🇺🇸
Maricopa Medical Center - Emergency Medicine, Phoenix, Arizona, United States
🇺🇸
Johns Hopkins University at Mount Washington - Emergency Medicine, Baltimore, Maryland, United States

and more 2 locations

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

Completed

Conditions: HIV Infections

Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate
Drug: Emtricitabine/tenofovir disoproxil fumarate placebo
Drug: Tenofovir disoproxil fumarate
Drug: Tenofovir disoproxil fumarate placebo

First Posted Date: 2008-08-07

Last Posted Date: 2023-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 518

Registration Number: NCT00729573

Locations: 🇿🇼
Seke South CRS, Chitungwiza, Zimbabwe
🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇿🇼
Zengeza CRS, Chitungwiza, Zimbabwe

and more 1 locations

Linezolid to Treat Extensively-Drug Resistant Tuberculosis

Phase 2

Completed

Conditions: Multidrug Resistant Tuberculosis
Extensively Drug Resistant Tuberculosis
Pulmonary Tuberculosis

Interventions: Drug: Immediate Start Linezolid
Drug: Delayed Start Linezolid

First Posted Date: 2008-08-04

Last Posted Date: 2016-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 41

Registration Number: NCT00727844

Locations: 🇰🇷
National Medical Center, Seoul, Korea, Republic of
🇰🇷
National Masan Tuberculosis Hospital, Changwon, Korea, Republic of

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Live Yellow Fever Vaccine (YFV-17D)
Drug: YFV-17D Placebo

First Posted Date: 2008-07-28

Last Posted Date: 2014-01-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 82

Registration Number: NCT00723489

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

Phase 1

Completed

Conditions: Influenza
Virus Diseases

Interventions: Biological: H2N2 1960 AA ca recombinant vaccine

First Posted Date: 2008-07-28

Last Posted Date: 2008-11-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00722774

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, CIR Unit at the Mason F Lord Building, Baltimore, Maryland, United States

Cause of Unexplained Anaphylaxis

Active, not recruiting

Conditions: Idiopathic Anaphylaxis
Drug Anaphylaxis
Venom Anaphylaxis
Food Anaphylaxis

First Posted Date: 2008-07-22

Last Posted Date: 2025-06-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 115

Registration Number: NCT00719719

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: rDEN3-3'D4delta30

First Posted Date: 2008-07-10

Last Posted Date: 2013-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 29

Registration Number: NCT00712803

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins University of Public Health, Baltimore, Maryland, United States
🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Washington, District of Columbia, United States

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2008-07-03

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 31

Registration Number: NCT00709605

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Vitamin D3 in Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: SLE
Lupus
Systemic Lupus Erythematosus

Interventions: Drug: Vitamin D3 placebo
Drug: Vitamin D3

First Posted Date: 2008-07-03

Last Posted Date: 2017-04-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT00710021

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy